Keith S. Bahjat

4.7k citations

46 papers · 3.3k indexed · 1 hit paper · h-index 24

Co-authors: Lukasz J. Ochyl Anna Schwendeman James J. Moon Rui Kuai Thomas W. Dubensky Dirk G. Brockstedt Marka R. Crittenden Shelly Bambina
Topics: Immunotherapy and Immune Responses (28 papers)Cancer Immunotherapy and Biomarkers (10 papers)Cancer Research and Treatments (9 papers)
Cited by: Immunology Biotechnology Oncology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Investigation Nature Medicine
Partner nations: United States Germany Japan

In The Last Decade

Keith S. Bahjat

46 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Designer vaccine nanodiscs for personalized cancer immunotherapy

2016 879 citations Rui Kuai, Lukasz J. Ochyl et al. Nature Materials profile →

Peers

Countries citing papers authored by Keith S. Bahjat

Since Specialization

Citations

This map shows the geographic impact of Keith S. Bahjat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith S. Bahjat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith S. Bahjat more than expected).

Fields of papers citing papers by Keith S. Bahjat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith S. Bahjat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith S. Bahjat. The network helps show where Keith S. Bahjat may publish in the future.

Co-authorship network of co-authors of Keith S. Bahjat

This figure shows the co-authorship network connecting the top 25 collaborators of Keith S. Bahjat. A scholar is included among the top collaborators of Keith S. Bahjat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith S. Bahjat. Keith S. Bahjat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Listeria monocytogenes-infected human monocytic derived dendritic cells activate Vγ9Vδ2 T cells independently of HMBPP production 2021 ·Scientific Reports ·Alejandro Alice,Gwen Kramer,Shelly Bambina,Keith S. Bahjat,Michael J. Gough,Marka R. Crittenden	6
2	Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells 2020 ·Frontiers in Immunology ·Chen Zhu,Zhili Song,Anlai Wang,Srimathi Srinivasan,Guang Yang,Rita Greco,Joachim Theilhaber,(unknown),Lan Wu,Zhiyong Yang,(unknown),Alain Fournier,Yu‐Tzu Tai,Kenneth C. Anderson,Dmitri Wiederschain,Keith S. Bahjat,Francisco Adrián,Marielle Chiron	85
3	A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity 2019 ·PLoS ONE ·(unknown),Shelly Bambina,(unknown),Alejandro Alice,Kyra D. Zens,Peter Lauer,Bill Hanson,Michael J. Gough,Marka R. Crittenden,Keith S. Bahjat	19
4	P2.02-043 Randomized Ph II Trial of Allogeneic DPV-001 Cancer Vaccine Alone or with Adjuvant for Curatively-Treated Stage III NSCLC 2017 ·Journal of Thoracic Oncology ·Rachel E. Sanborn,Brian C. Boulmay,Rui Li,(unknown),Sachin Puri,Christopher Paustian,Christopher Dubay,Sandra Aung,Brenda Fisher,Carlo Bifulco,Keith S. Bahjat,Yoshinobu Koguchi,Augusto C. Ochoa,Hong‐Ming Hu,Traci Hilton,Bernard A. Fox,Walter J. Urba	2
5	Designer vaccine nanodiscs for personalized cancer immunotherapybreakdown → 2016 ·Nature Materials ·Rui Kuai,Lukasz J. Ochyl,Keith S. Bahjat,Anna Schwendeman,James J. Moon	879
6	A Semi-automated Approach to Preparing Antibody Cocktails for Immunophenotypic Analysis of Human Peripheral Blood 2016 ·Journal of Visualized Experiments ·Yoshinobu Koguchi,(unknown),Tanisha Meeuwsen,William L. Miller,Daniel Haley,(unknown),Keith S. Bahjat	4
7	Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab 2015 ·Cancer Research ·Yoshinobu Koguchi,Helena Hoen,Shelly Bambina,(unknown),(unknown),Brendan D. Curti,Walter J. Urba,Christina Milburn,Frances Rena Bahjat,Alan J. Korman,Keith S. Bahjat	39
8	Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors 2015 ·Cancer Research ·Jason R. Baird,David J. Friedman,Benjamin Cottam,Thomas W. Dubensky,David B. Kanne,Shelly Bambina,Keith S. Bahjat,Marka R. Crittenden,Michael J. Gough	201
9	A Self-Help Program for Memory CD8+ T Cells: Positive Feedback via CD40-CD40L Signaling as a Critical Determinant of Secondary Expansion 2013 ·PLoS ONE ·(unknown),Shelly Bambina,Alejandro Alice,Ryan Montler,Keith S. Bahjat	10
10	CD8+ T Cell Priming by Dendritic Cell Vaccines Requires Antigen Transfer to Endogenous Antigen Presenting Cells 2010 ·PLoS ONE ·Alice Yewdall,Scott Drutman,(unknown),Keith S. Bahjat,Nina Bhardwaj	111
11	Suppression of Cell-Mediated Immunity following Recognition of Phagosome-Confined Bacteria 2009 ·PLoS Pathogens ·Keith S. Bahjat,Nicole Meyer-Morse,Edward E. Lemmens,(unknown),Thomas W. Dubensky,Dirk G. Brockstedt,Daniel A. Portnoy	27
12	KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity 2008 ·Journal of Clinical Investigation ·Mojca Škoberne,Alice Yewdall,Keith S. Bahjat,Emmanuelle Godefroy,Peter Lauer,Edward E. Lemmens,Weiqun Liu,(unknown),Meredith L. Leong,Thomas W. Dubensky,Dirk G. Brockstedt,Nina Bhardwaj	35
13	Activation of Immature Hepatic NK Cells As Immunotherapy for Liver Metastatic Disease 2007 ·The Journal of Immunology ·Keith S. Bahjat,Rodney A. Prell,Heather E. Allen,Weiqun Liu,Edward E. Lemmens,Meredith L. Leong,Daniel A. Portnoy,Thomas W. Dubensky,Dirk G. Brockstedt,Martin Giedlin	21
14	Selective Targeting of Antitumor Immune Responses with Engineered Live-Attenuated Listeria monocytogenes 2006 ·Cancer Research ·Kiyoshi Yoshimura,Ajay Jain,Heather E. Allen,(unknown),Christina Y. Chia,Sowmya Ravi,Dirk G. Brockstedt,Martin Giedlin,Keith S. Bahjat,Meredith L. Leong,Jill E. Slansky,David N. Cook,Thomas W. Dubensky,Drew M. Pardoll,Richard D. Schulick	48
15	Efficient T Cell Activation via a Toll-Interleukin 1 Receptor-Independent Pathway 2006 ·Immunity ·Edith M. Janssen,Koichi Tabeta,Michael J. Barnes,Sophie Rutschmann,Sara W. McBride,Keith S. Bahjat,Stephen P. Schoenberger,Argyrios N. Theofilopoulos,Bruce Beutler,Kasper Hoebe	81
16	Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity 2005 ·Nature Medicine ·Dirk G. Brockstedt,Keith S. Bahjat,Martin Giedlin,(unknown),(unknown),William Luckett,Yi Gao,Pamela Schnupf,(unknown),(unknown),(unknown),Adam Sampson-Johannes,Anat A. Herskovits,Adonis Stassinopoulos,H. G. Archie Bouwer,J Hearst,Daniel A. Portnoy,David N. Cook,Thomas W. Dubensky	114
17	In Vivo Transduction of Thymic Dendritic Cells with Adenovirus and Its Potential Use in Acute Inflammatory Diseases 2005 ·Scandinavian Journal of Immunology ·Caroline Oberholzer,Sven K. Tschoeke,Keith S. Bahjat,Drake LaFace,Beth Hutchins,Michael Clare‐Salzler,Lyle L. Moldawer,A. Oberholzer	3
18	Killed but Metabolically Active Recombinant Listeria monocytogenes as an Antigen Delivery and Activation Platform for Human Dendritic Cell-Based Cancer Immunotherapy. 2004 ·Blood ·Dirk G. Brockstedt,Mojca Škoberne,Alice Yewdall,Keith S. Bahjat,(unknown),Thomas W. Dubensky,Nina Bhardwaj	2
19	Increased Survival in Sepsis by In Vivo Adenovirus-Induced Expression of IL-10 in Dendritic Cells 2002 ·The Journal of Immunology ·Andreas Oberholzer,Caroline Oberholzer,Keith S. Bahjat,Ricardo Ungaro,Cynthia L. Tannahill,(unknown),Frances Rena Bahjat,Zaher Abouhamze,Van Tsai,Drake LaFace,Beth Hutchins,Lyle L. Moldawer,Michael Clare‐Salzler	49
20	INCREASED EXPRESSION OF THE LYMPHOCYTE EARLY ACTIVATION MARKER CD69 IN PERIPHERAL BLOOD CORRELATES WITH HISTOLOGIC EVIDENCE OF CARDIAC ALLOGRAFT REJECTION1 2000 ·Transplantation ·Kenneth O. Schowengerdt,F. Jay Fricker,Keith S. Bahjat,(unknown)	36

About Keith S. Bahjat

Keith S. Bahjat is a scholar working on Immunology, Biotechnology and Oncology, having authored 46 papers that have together received 3.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (28 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Cancer Research and Treatments (9 papers). The work is most often cited by research in Immunology (2.2k citations), Biotechnology (408 citations) and Oncology (1.1k citations). Keith S. Bahjat has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include Lukasz J. Ochyl, Anna Schwendeman, James J. Moon, Rui Kuai, Thomas W. Dubensky, Dirk G. Brockstedt, Marka R. Crittenden, Shelly Bambina, Michael J. Gough and Benjamin Cottam. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact